Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2008

View Archived Issues

Increased gastrointestinal motility with Elixir's novel ghrelin receptor agonist

LGD-2941 well tolerated, orally bioavailable in healthy subjects

Novel histamine H3 receptor inverse agonist profiled at Banyu

Novartis acquires 25% stake in Alcon as part of definitive agreement with Nestle

Inovio and VGX sign merger agreement

Medivation reports positive results from phase II study of Dimebon in HD

Provectus treats first 25% of melanoma subjects in phase II clinical trial of PV-10

Phase I study explores DNA-hsp65 immunotherapy in head and neck cancer

Sendai virus vaccines protect against parainfluenza and respiratory syncytial viruses in vivo

GeoVax to initiate phase II human trials with preventative AIDS vaccine

Light Sciences Oncology begins clinical trials of Litx therapy in patients with BPH

Novel agents for treating HCV infection disclosed in recent Genelabs patents

Seattle Genetics enters into antibody-drug conjugate collaboration with Daiichi Sankyo

Recent patents describe new treatment options for endocrine-related disorders

Anadys receives clearance in the Netherlands for phase I clinical trial of ANA-773

New antithrombotic agents divulged in recent patent literature

Sciele Pharma completes phase III safety trial for glycopyrrolate and plans to file an NDA

Pharmasset initiates combination study of clevudine and Viread for HBV

TIPO-4 extension study confirms tesofensine's efficacy in weight management

Teva reports results from phase III FORTE study of glatiramer acetate 40 mg in RRMS

Tumor-targeted Rexin-G receives FDA orphan drug designation for osteosarcoma

Immatics receives research grants for cancer research totaling EUR 1.4 million

FoldRx discovers series of novel drug prototypes for treatment of cystic fibrosis

Amorfix on schedule to complete antibody infusion studies in mice of therapy for ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...